You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRisedronate
Accession NumberDB00884  (APRD00410, DB02782)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRisedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
Structure
Thumb
Synonyms
Acide risédroniqe
Acido risedronico
Acidum risedronicum
Ridron
Risedronate
Risedronic acid
Risedronsäure
External Identifiers
  • NE-58095
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActonelTablet30 mgOralWarner Chilcott Canada Co1999-09-07Not applicableCanada
ActonelTablet, film coated30 mg/1OralWarner Chilcott Pharmaceuticals Inc.1998-03-27Not applicableUs
ActonelTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2002-03-15Not applicableUs
ActonelTablet5 mgOralWarner Chilcott Canada Co2000-07-25Not applicableCanada
ActonelTablet, film coated5 mg/1OralWarner Chilcott Pharmaceuticals Inc.2000-04-14Not applicableUs
ActonelTablet, film coated35 mg/1OralPhysicians Total Care, Inc.2002-09-16Not applicableUs
ActonelTablet35 mgOralWarner Chilcott Canada Co2002-12-10Not applicableCanada
ActonelTablet, film coated35 mg/1OralWarner Chilcott Pharmaceuticals Inc.2002-05-17Not applicableUs
ActonelTablet75 mgOralWarner Chilcott Canada Co2007-08-132016-08-05Canada
ActonelTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2009-10-05Not applicableUs
ActonelTablet150 mgOralWarner Chilcott Canada Co2008-12-01Not applicableCanada
ActonelTablet, film coated150 mg/1OralWarner Chilcott Pharmaceuticals Inc.2008-04-22Not applicableUs
Actonel DrTablet, delayed release35 mgOralWarner Chilcott Canada Co2011-08-10Not applicableCanada
Auro-risedronateTablet30 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-risedronateTablet35 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-risedronateTablet150 mgOralAuro Pharma Inc2016-04-13Not applicableCanada
Auro-risedronateTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada
Dom-risedronateTablet35 mgOralDominion Pharmacal2011-04-19Not applicableCanada
Jamp-risedronateTablet35 mgOralJamp Pharma Corporation2011-10-04Not applicableCanada
Mylan-risedronateTablet150 mgOralMylan Pharmaceuticals Ulc2013-09-30Not applicableCanada
Mylan-risedronateTablet35 mgOralMylan Pharmaceuticals Ulc2011-06-16Not applicableCanada
Ntp-risedronateTablet35 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-risedronateTablet5 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-risedronateTablet30 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Pendo-risedronateTablet35 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-risedronateTablet35 mgOralPharmel IncNot applicableNot applicableCanada
PMS-risedronateTablet150 mgOralPharmascience Inc2014-05-28Not applicableCanada
PMS-risedronateTablet35 mgOralPharmascience Inc2010-07-27Not applicableCanada
Q-risedronateTablet35 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ratio-risedronateTablet35 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-07-272015-10-26Canada
RisedronateTablet35 mgOralSivem Pharmaceuticals Ulc2011-04-08Not applicableCanada
RisedronateTablet5 mgOralSanis Health IncNot applicableNot applicableCanada
RisedronateTablet30 mgOralSanis Health IncNot applicableNot applicableCanada
RisedronateTablet35 mgOralSanis Health Inc2011-10-18Not applicableCanada
RisedronateTablet35 mgOralPro Doc Limitee2010-10-15Not applicableCanada
Risedronate-35Tablet35 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Riva-risedronateTablet35 mgOralLaboratoire Riva Inc2010-07-28Not applicableCanada
Sandoz RisedronateTablet35 mgOralSandoz Canada Incorporated2010-07-28Not applicableCanada
Teva-risedronateTablet150 mgOralTeva Canada Limited2013-10-10Not applicableCanada
Teva-risedronateTablet5 mgOralTeva Canada Limited2010-01-27Not applicableCanada
Teva-risedronateTablet30 mgOralTeva Canada Limited2010-01-27Not applicableCanada
Teva-risedronateTablet35 mgOralTeva Canada Limited2010-01-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-risedronateTablet35 mgOralApotex Inc2010-11-10Not applicableCanada
Apo-risedronateTablet150 mgOralApotex Inc2012-05-17Not applicableCanada
Risedronate SodiumTablet, film coated150 mg/1OralApotex Corp.2014-06-11Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated150 mg/1OralSun Pharma Global FZE2014-06-11Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate SodiumTablet, film coated5 mg/1OralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralApotex Corp.2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated75 mg/1OralMylan Pharmaceuticals Inc.2014-06-102016-01-07Us
Risedronate SodiumTablet, film coated5 mg/1OralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated5 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated5 mg/1OralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
Risedronate SodiumTablet, film coated150 mg/1OralTeva Pharmaceuticals Usa, Inc.2016-08-30Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated75 mg/1OralApotex Corp.2014-06-11Not applicableUs
Risedronate SodiumTablet, film coated150 mg/1OralMylan Pharmaceuticals Inc.2014-06-10Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
Risedronate SodiumTablet, film coated150 mg/1OralAurobindo Pharma Limited2016-10-21Not applicableUs
Risedronate SodiumTablet, delayed release35 mg/1OralTeva Pharmaceuticals USA Inc2015-05-18Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated75 mg/1OralSun Pharma Global FZE2014-06-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BenetTakeda
Brand mixtures
NameLabellerIngredients
ActonelWarner Chilcott (US), LLC
Actonel Plus CalciumWarner Chilcott Canada Co
Actonel Sachet KitWarner Chilcott Canada Co
AtelviaWarner Chilcott (US), LLC
PMS-risedronate Plus CalciumPharmascience Inc
Risedronate SodiumActavis Pharma, Inc.
Salts
Name/CASStructureProperties
Risedronate sodium
Thumb
  • InChI Key: DRFDPXKCEWYIAW-UHFFFAOYNA-M
  • Monoisotopic Mass: 304.983019378
  • Average Mass: 305.0941
DBSALT000494
Risedronate sodium hemi-pentahydrate
ThumbNot applicableDBSALT001515
Risedronate sodium monohydrate
ThumbNot applicableDBSALT001516
Categories
UNIIKM2Z91756Z
CAS number105462-24-6
WeightAverage: 283.1123
Monoisotopic: 283.001074735
Chemical FormulaC7H11NO7P2
InChI KeyIIDJRNMFWXDHID-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
IUPAC Name
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
SMILES
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Pharmacology
IndicationFor the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis
Structured Indications
PharmacodynamicsRisedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Mechanism of actionThe action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
TargetKindPharmacological actionActionsOrganismUniProt ID
Farnesyl pyrophosphate synthaseProteinyes
inhibitor
HumanP14324 details
HydroxylapatiteSmall moleculeyes
antagonist
Humannot applicabledetails
Related Articles
AbsorptionRapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract
Volume of distribution
  • 13.8 L/kg
Protein binding~24%
Metabolism

No evidence found for metabolization of risedronate in humans or mammals

Route of eliminationRisedronate is excreted unchanged primarily via the kidney. Insignificant amounts (<0.1% of intravenous dose) of drug are excreted in the bile in rats.
Half life1.5 hours
Clearance
  • 122 mL/min
  • 73 mL/min [osteopenic postmenopausal women]
ToxicitySide effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Risedronate Action PathwayDrug actionSMP00112
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Risedronate.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Risedronate.Vet Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Risedronate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Risedronate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Risedronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Risedronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Risedronate.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Risedronate.Approved, Investigational
Aluminum hydroxideThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum phosphate.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
AmobarbitalThe metabolism of Risedronate can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Risedronate.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Risedronate.Approved, Investigational
AmrubicinAmrubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Risedronate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Risedronate.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Risedronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Risedronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.Approved
ApramycinApramycin may increase the hypocalcemic activities of Risedronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Risedronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Risedronate.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.Approved
AsenapineThe serum concentration of Risedronate can be increased when it is combined with Asenapine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Risedronate is combined with Atosiban.Approved
Atracurium besylateRisedronate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Risedronate.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Risedronate.Approved, Investigational
BarbexacloneThe metabolism of Risedronate can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Risedronate can be increased when combined with Barbital.Illicit
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Risedronate.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Risedronate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Risedronate.Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Risedronate.Approved
Bismuth SubcitrateThe serum concentration of Risedronate can be decreased when it is combined with Bismuth Subcitrate.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Risedronate.Investigational
BucindololBucindolol may increase the hypotensive activities of Risedronate.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Risedronate.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Risedronate.Approved
CalciumThe serum concentration of Risedronate can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium carbonateThe serum concentration of Risedronate can be decreased when it is combined with Calcium carbonate.Approved
Calcium ChlorideThe serum concentration of Risedronate can be decreased when it is combined with Calcium Chloride.Approved
Calcium citrateThe serum concentration of Risedronate can be decreased when it is combined with Calcium citrate.Approved
Calcium glubionateThe serum concentration of Risedronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Risedronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Risedronate.Withdrawn
CarbomycinThe metabolism of Risedronate can be decreased when combined with Carbomycin.Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Risedronate.Approved, Vet Approved, Withdrawn
CarvedilolCarvedilol may increase the hypotensive activities of Risedronate.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Risedronate.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Risedronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Risedronate.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Risedronate.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Risedronate.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronate.Approved, Investigational
CimetidineThe serum concentration of Risedronate can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Risedronate can be decreased when combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Risedronate.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronate.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Risedronate.Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Risedronate.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Risedronate.Investigational
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Risedronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Risedronate.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Risedronate.Experimental
DeferasiroxThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Risedronate.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Risedronate.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Risedronate.Approved
DoxepinThe serum concentration of Risedronate can be increased when it is combined with Doxepin.Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Risedronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Risedronate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Risedronate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Risedronate.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Risedronate.Approved
EfavirenzThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Risedronate.Approved
EpinastineThe serum concentration of Risedronate can be increased when it is combined with Epinastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Risedronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Risedronate.Approved
ErythromycinThe metabolism of Risedronate can be decreased when combined with Erythromycin.Approved, Vet Approved
EsomeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Risedronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Risedronate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Risedronate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Risedronate.Investigational
FamotidineThe serum concentration of Risedronate can be increased when it is combined with Famotidine.Approved
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Risedronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Risedronate.Approved
Ferric CitrateThe serum concentration of Risedronate can be decreased when it is combined with Ferric Citrate.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Risedronate.Approved, Withdrawn
FluconazoleThe serum concentration of Risedronate can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Risedronate.Approved
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Risedronate.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Risedronate.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Risedronate.Approved
FramycetinFramycetin may increase the hypocalcemic activities of Risedronate.Approved
GeneticinGeneticin may increase the hypocalcemic activities of Risedronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Risedronate.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Risedronate.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Risedronate.Approved, Vet Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Risedronate.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Risedronate.Approved
HexobarbitalThe metabolism of Risedronate can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Risedronate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Risedronate.Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Risedronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Risedronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Risedronate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Risedronate.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Risedronate.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Risedronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Risedronate.Investigational
Iron saccharateThe serum concentration of Risedronate can be decreased when it is combined with Iron saccharate.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Risedronate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Risedronate.Withdrawn
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronate.Approved, Investigational
JosamycinThe metabolism of Risedronate can be decreased when combined with Josamycin.Approved
KanamycinKanamycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Risedronate.Experimental
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronate.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.Approved
KitasamycinThe metabolism of Risedronate can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Risedronate.Approved
LansoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Risedronate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Risedronate.Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Risedronate.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Risedronate.Approved, Investigational
Magnesium carbonateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Risedronate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Risedronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Risedronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.Withdrawn
MethanthelineThe serum concentration of Risedronate can be increased when it is combined with Methantheline.Approved
MethohexitalThe metabolism of Risedronate can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Risedronate can be increased when combined with Methylphenobarbital.Approved
MetiamideThe serum concentration of Risedronate can be increased when it is combined with Metiamide.Experimental
MetrizamideMetrizamide may increase the hypocalcemic activities of Risedronate.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Risedronate.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Risedronate.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Risedronate.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Risedronate.Approved
MivacuriumRisedronate may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Risedronate.Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Risedronate.Vet Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Risedronate.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Risedronate.Investigational
NafcillinThe metabolism of Risedronate can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Risedronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Risedronate.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Risedronate.Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Risedronate.Investigational
NeamineNeamine may increase the hypocalcemic activities of Risedronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Risedronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Risedronate.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Risedronate.Investigational
NitroprussideRisedronate may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Risedronate.Approved
NizatidineThe serum concentration of Risedronate can be increased when it is combined with Nizatidine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Risedronate.Approved, Vet Approved
OlanzapineThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Risedronate can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.Approved
OmeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Risedronate.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Risedronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.Withdrawn
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Risedronate.Investigational
PantoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Risedronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Risedronate.Approved
PentobarbitalThe metabolism of Risedronate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Risedronate can be increased when combined with Phenobarbital.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Risedronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.Approved, Investigational
PirarubicinPirarubicin may increase the hypocalcemic activities of Risedronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.Approved, Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Risedronate.Approved, Withdrawn
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronate.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Risedronate.Approved
PrimidoneThe metabolism of Risedronate can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Risedronate.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Risedronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Risedronate.Experimental
RabeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Risedronate.Experimental
RanitidineThe serum concentration of Risedronate can be increased when it is combined with Ranitidine.Approved
RapacuroniumRisedronate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Risedronate.Approved
RifabutinThe serum concentration of Risedronate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Risedronate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Risedronate can be decreased when it is combined with Rifapentine.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Risedronate.Investigational, Withdrawn
Roxatidine acetateThe serum concentration of Risedronate can be increased when it is combined with Roxatidine acetate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Risedronate.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Risedronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.Approved
SecobarbitalThe metabolism of Risedronate can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Risedronate.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Risedronate.Approved
SilodosinSilodosin may increase the hypotensive activities of Risedronate.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Risedronate.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Risedronate.Approved, Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Risedronate.Investigational
SolithromycinThe metabolism of Risedronate can be decreased when combined with Solithromycin.Investigational
SP1049CSP1049C may increase the hypocalcemic activities of Risedronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Risedronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Risedronate.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Risedronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Risedronate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Risedronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.Approved, Withdrawn
TAK-390MRThe therapeutic efficacy of Risedronate can be decreased when used in combination with TAK-390MR.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Risedronate.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Risedronate.Approved
TelithromycinThe metabolism of Risedronate can be decreased when combined with Telithromycin.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Risedronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Risedronate.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Risedronate.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Risedronate.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Risedronate.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Risedronate.Approved
ThiamylalThe metabolism of Risedronate can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Risedronate can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Risedronate.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Risedronate.Investigational
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronate.Approved
TobramycinTobramycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Risedronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Risedronate.Approved, Vet Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Risedronate.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Risedronate.Approved, Investigational
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Risedronate.Approved
TroleandomycinThe metabolism of Risedronate can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Risedronate can be decreased when combined with Tylosin.Vet Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Risedronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Risedronate.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronate.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Risedronate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.Withdrawn
ZorubicinZorubicin may increase the hypocalcemic activities of Risedronate.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Srinivasa Rao V.N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala, “Process for the preparation of risedronate sodium hemi-pentahydrate.” U.S. Patent US20070173484, issued July 26, 2007.

US20070173484
General ReferencesNot Available
External Links
ATC CodesM05BB02M05BA07M05BB04M05BB07
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (1.52 MB)
MSDSDownload (57 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9357
Blood Brain Barrier+0.9172
Caco-2 permeable-0.6795
P-glycoprotein substrateNon-substrate0.6846
P-glycoprotein inhibitor INon-inhibitor0.9582
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9542
CYP450 2C9 substrateNon-substrate0.8452
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateNon-inhibitor0.8778
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.9062
CYP450 2C19 inhibitorNon-inhibitor0.8777
CYP450 3A4 inhibitorNon-inhibitor0.9068
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.989
Ames testNon AMES toxic0.7663
CarcinogenicityNon-carcinogens0.8386
BiodegradationNot ready biodegradable0.5058
Rat acute toxicity2.1053 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9095
hERG inhibition (predictor II)Non-inhibitor0.9303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Warner chilcott co llc
  • Teva pharmaceuticals usa
  • Procter & Gamble
Packagers
Dosage forms
FormRouteStrength
TabletOral75 mg
Tablet, film coatedOral150 mg/1
Tablet, delayed releaseOral35 mg
Granule, effervescent; kit; tabletOral
TabletOral150 mg
Tablet, delayed releaseOral
TabletOral
Tablet, delayed releaseOral35 mg/1
Tablet, film coatedOral
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral35 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral75 mg/1
TabletOral30 mg
TabletOral35 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Actonel 150 mg tablet125.1USD tablet
Actonel 4 35 mg tablet Disp Pack119.43USD disp
Actonel 75 mg tablet54.83USD tablet
Actonel 30 mg tablet29.32USD tablet
Actonel 35 mg tablet28.75USD tablet
Actonel 5 mg tablet4.13USD tablet
Actonel with calcium tablet3.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2294595 No2001-08-212018-07-17Canada
CA2399976 No2007-03-272021-02-01Canada
US5994329 Yes1999-01-172019-01-17Us
US6015801 Yes1999-01-172019-01-17Us
US6096342 No1994-11-222011-11-22Us
US6165513 Yes1998-12-102018-12-10Us
US6432932 Yes1999-01-172019-01-17Us
US6465443 Yes1999-02-142019-02-14Us
US7192938 Yes2003-11-062023-11-06Us
US7645459 No2008-01-092028-01-09Us
US7645460 No2008-01-092028-01-09Us
US7718634 Yes2003-11-062023-11-06Us
US8246989 No2006-01-162026-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP-0.75ALOGPS
logP-3.3ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.68ChemAxon
pKa (Strongest Basic)4.91ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area148.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity57.12 m3·mol-1ChemAxon
Polarizability21.91 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Pyridine
  • Heteroaromatic compound
  • Organophosphonic acid
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Poly(a) rna binding
Specific Function:
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, d...
Gene Name:
FDPS
Uniprot ID:
P14324
Molecular Weight:
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58. [PubMed:16006204 ]
  4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603 ]
  5. Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64. [PubMed:16835450 ]
  6. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. [PubMed:18056045 ]
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. doi: 10.1186/ar3122. Epub 2010 Aug 25. [PubMed:20738860 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58